华兰股份(301093.SZ)拟斥4.5亿元增资灵擎数智 完善AI医药领域战略布局

Core Viewpoint - The company has approved a capital increase of 450 million yuan to its wholly-owned subsidiary, Lingqing Smart Pharmaceutical Technology Co., Ltd., which focuses on AI-driven drug research and development solutions [1] Group 1: Company Strategy - The capital increase aims to enhance the company's strategic layout in the AI pharmaceutical sector [1] - The investment will strengthen the company's capability for continuous investment in cutting-edge technologies and industry collaboration [1] Group 2: Business Development - The funding is expected to promote the steady development and commercialization of the company's AI pharmaceutical business [1]